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Together with aspartate, glutamate is the major excitatory neurotransmitter in the brain.
Glutamate binds and activates both ligand-gated ion channels (ionotropic glutamate
receptors) and a class of G-protein coupled receptors (metabotropic glutamate
receptors). Although the intracellular glutamate concentration in the brain is in the
millimolar range, the extracellular glutamate concentration is kept in the low micromolar
range by the action of excitatory amino acid transporters that import glutamate
and aspartate into astrocytes and neurons. Excess extracellular glutamate may lead
to excitotoxicity in vitro and in vivo in acute insults like ischemic stroke via the
overactivation of ionotropic glutamate receptors. In addition, chronic excitotoxicity has
been hypothesized to play a role in numerous neurodegenerative diseases including
amyotrophic lateral sclerosis, Alzheimer’s disease and Huntington’s disease. Based on
this hypothesis, a good deal of effort has been devoted to develop and test drugs that
either inhibit glutamate receptors or decrease extracellular glutamate. In this review,
we provide an overview of the different pathways that are thought to lead to an
over-activation of the glutamatergic system and glutamate toxicity in neurodegeneration.
In addition, we summarize the available experimental evidence for glutamate toxicity in
animal models of neurodegenerative diseases.
Keywords: glutamate receptors, glutamate transporters, system x−c , Alzheimer’s disease, Huntington’s disease,
amyotrophic lateral sclerosis, neurodegeneration, excitotoxicity
INTRODUCTION
L-glutamate (L-glu) is the major excitatory neurotransmitter in the brain and is functionally
involved in virtually all activities of the nervous system. In this section, we will first outline
the general principles of L-glu signaling in the brain. Then, we will broaden this scheme by
expanding the model to (a) different pools of extracellular glutamate (synaptic, perisynaptic,
and extrasynaptic) resulting from either vesicular and non-vesicular sources or atypically located
glutamate receptors outside of synapses and (b) other molecules present in the brain that have the
ability to activate glutamate receptors and discuss their possible physiological functions.
Glutamate Signaling in the Brain
The human brain contains 6–7µmol/g wet weight of L-glu (Perry et al., 1971; Lefauconnier et al.,
1976). Thus, L-glu along with glutamine is themost abundant free amino acid in the central nervous
system. More than five decades ago, Curtis et al. demonstrated that L-glu has an excitatory action
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on nerve cells (Curtis et al., 1960). Since then, its role as an
excitatory neurotransmitter as well as its cerebral metabolism
have been studied in detail (reviewed by Fonnum, 1984; Hertz,
2006; Marmiroli and Cavaletti, 2012; Zhou and Danbolt, 2014).
L-glu is concentrated in synaptic vesicles in the presynaptic
terminal by the action of vesicular glutamate transporters
(vGLUT; Takamori, 2006). In addition, some of the L-glu in
the vesicles might be generated by a vesicle-associated aspartate
amino transferase from 2-oxoglutarate using L-aspartate (L-
asp) as the amino group donor (Takeda et al., 2012). Upon
depolarization of the presynaptic membrane, L-glu is released
into the synaptic cleft and binds to ionotropic glutamate
receptors (iGluRs) at the postsynaptic membrane (Figure 1).
iGluRs are ligand-gated ion channels and include receptors
of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA), kainate, and N-methyl-D-aspartic acid (NMDA) types
(reviewed in Lodge, 2009). While AMPA and kainate receptors
primarily mediate sodium influx, NMDA receptors have high
calcium conductivity. Activation of NMDA receptors plays an
important role in synaptic plasticity and learning (reviewed in
Miyamoto, 2006). In contrast to the other iGluRs, the activity
of NMDA receptors is inhibited by a so-called Mg+2 block at
the regular membrane potential but the ion channel is readily
de-blocked by membrane depolarization, which removes Mg+2
from the pore (Vargas-Caballero and Robinson, 2004). NMDA
receptors are tetramers containing two NR1 subunits and two
NR2 or NR3 subunits (Paoletti and Neyton, 2007).
In addition to iGluRs, eight isoforms of metabotropic
glutamate receptors (mGluRs; Spooren et al., 2010) exist, which
belong to the family of G-protein-coupled receptors and do not
form ion channels but rather signal via various second messenger
systems (reviewed in Spooren et al., 2010). L-glu-induced
depolarization leads to a postsynaptic excitatory potential which
facilitates the generation of an action potential at the axon hillock.
The glutamatergic synapse is ensheathed by astrocytic processes
that express high levels of excitatory amino acid transporters
(EAATs; Chaudhry et al., 1995). Five different EAATs exist,
EAAT1-5, of which EAAT1 and 2 are the primary astrocytic
EAATs, whereas EAAT3 shows a predominantly neuronal
Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; ADME, absorption,
distribution, metabolism, and excretion; ALS, amyotrophic lateral sclerosis;
ALS/PDC, Guamian amyotrophic lateral sclerosis/Parkinson-dementia
complex; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANA,
anthranilic acid; APP, amyloid precursor protein; Asc-1, alanine-serine-cysteine
amino acid transporter 1; L-asp, aspartate; BMAA, β-N-methylamino-L-
alanine; BOAA, β-N-oxalylamino-L-alanine; Cef, ceftriaxone; CREB, cyclicAMP
response element-binding protein; CSF, cerebral spinal fluid; CNS, central
nervous system; DAO, D-amino acid oxidase; DIV, days in vitro; EAAT,
excitatory amino acid transporter; GFAP, glial fibrillary acidic protein; iGluR,
ionotropic glutamate receptor; L-glu, glutamate; 3HANA, 3-hydroxyanthranilic
acid; 3-HAO, 3-hydroxyanthranilate oxidase; L-HCA, homocysteate; HD,
Huntington’s disease; 3HK, 3-hydroxykynurenine; Htt, huntingtin protein;
IDO, indoleamine 2,3-dioxygenase; KAT, kynurenine aminotransferase; KMO,
kynurenine monoxygenase; KYN, kynurenine; KYNA, kynurenic acid; MAPK,
mitogen activate protein kinase; mGluR, metabotropic glutamate receptors; MSN,
medium spiny neurons; NMDA, N-methyl-D-aspartic acid; QUIN, quinolinic
acid; SOD1, superoxide dismutase 1; SSZ, sulfasalazine; TBI, traumatic brain
injury, Tg, transgenic, TSC, tuberous sclerosis complex; vGLUT, vesicular
glutamate transporters; YAC, yeast artificial chromosome.
expression (Zhou and Danbolt, 2013). About 90% of the L-glu
transport is mediated by EAAT2 (aka GLT-1 in rodents). These
transporters co-transport 2 or 3 molecules of Na+ and a proton
with each molecule of L-glu (or L-asp) in conjunction with the
counter-transport of a K+ ion (Zerangue and Kavanaugh, 1996).
Thus, by using the electrochemical gradient of these ions across
the plasma membrane as an energy source, the transporters
are capable of effectively accumulating L-glu and L-asp in cells
against their steep intra- to extracellular concentration gradients.
This allows the brain to maintain a very low extracellular L-
glu concentration in the low micromolar range (Baker et al.,
2003; De Bundel et al., 2011). It is generally thought that L-glu
taken up by astrocytes is converted to glutamine by the enzyme
glutamine synthetase, the glutamine is then released, taken up
by neurons and converted to L-glu and used once again for
neurotransmission (Coulter and Eid, 2012).
The Role of Extrasynaptic Glutamate in the
Brain
Apart from the role of L-glu as the principal excitatory
neurotransmitter released from glutamatergic presynapses as
described above, it has become apparent that L-glu receptors
outside the synaptic cleft also play an important role in brain
physiology (Papouin and Oliet, 2014). In the cerebellum, it was
demonstrated by analyzing AMPA receptor-mediated currents
in Bergmann glia that synaptically released L-glu concentrations
can reach extrasynaptic concentrations of up to 190µM, while
concentrations in the synaptic cleft exceed 1mM (Dzubay and
Jahr, 1999). Moreover, some mGluRs have been shown to exhibit
a distinct localization in proximity to the postsynaptic density
that would allow them to readily detect L-glu leaking from
the synaptic cleft (Luján et al., 1997; Figure 1). However, in
recent years, evidence has accumulated that iGluRs, especially
of the NMDA type, are also present at extrasynaptic sites
in the neuronal cell membrane (Papouin and Oliet, 2014).
Using light and electron microscopy, Petralia et al. showed that
extrasynaptic NMDA receptors cluster at distinct sites of close
contact of the dendritic shaft with either axons, axon terminals,
or astrocytic processes (Petralia et al., 2010). The proportion of
extrasynaptic NMDA receptors was estimated to be as high as
36% of the dendritic NMDA receptor pool in rat hippocampal
slices (Harris and Pettit, 2007). Although extrasynaptic NMDA
receptors were associated with similar scaffolding proteins as
synaptic NMDA receptors (Petralia et al., 2010), an in vitro
study suggested that extrasynaptic and synaptic NMDA receptors
may activate different downstream signaling pathways with
contrasting results: suppression of CREB activity by extrasynaptic
NMDA receptor activation but activation by synaptic NMDA
receptors (Hardingham et al., 2002). Functionally, NMDA
receptors localized extrasynaptically on dendritic shafts bind
extrasynaptic L-glu and mediate Ca2+ influx upon relief of
the Mg+2 block by dendrite depolarization upon backfiring of
action potentials (Wu et al., 2012). Angulo et al. showed that
L-glu release from astrocytes can activate so-called slow inward
currents via extrasynaptic NMDAR receptors in CA1 neurons
which thereby can be synchronized (Angulo et al., 2004). Thus,
the mechanisms through which glial cells release L-glu as well
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FIGURE 1 | Glutamate metabolism in the brain. Vesicular glutamate is synaptically released and binds to ionotropic glutamate receptors at the postsynapse.
Glutamate is rapidly taken up by astrocytic glutamate transporters, especially EAAT2. Spillover from the synaptic cleft can activate perisynaptic mGluR5. Migroglia and
astrocytes non-vesicularly release glutamate into the extrasynaptic extracellular space via system x−c (x
−
c ) where it can activate extrasynaptic NMDA receptors.
as how the extrasynaptic L-glu concentrations are regulated
are pivotal to understanding how the activity of extrasynaptic
NMDA receptors are regulated.
Different mechanisms through which astrocytes can release
L-glu have been proposed: vesicular L-glu release (Adak et al.,
2000) and non-vesicular release via anion channels (Wang
et al., 2013) and connexin hemichannels (Stehberg et al.,
2012) as well as release via the cystine/glutamate antiporter
system x−c (Massie et al., 2015). Data by Wang et al. strongly
suggest that vesicular release from astrocytes plays a minor
role, as the Ca+2-mediated release of L-glu was still present
in astrocytes derived from dominant-negative SNARE mice
(Wang et al., 2013) where vesicular release can be blocked
by doxycycline withdrawal (Pascual et al., 2005). System x−c
is a cystine/glutamate antiporter which belongs to the class
of heterodimeric amino acid transporters, consisting of xCT
as the specific subunit and 4F2hc as the promiscuous heavy
chain (Sato et al., 1999). This transporter is expressed in the
brain, especially in astroglial and microglial cells (Fogal et al.,
2007; Mesci et al., 2015; Figure 1). The fact that extrasynaptic
L-glu levels in different areas of the brain are downregulated
by approximately 60–70% in xCT knock out mice (De Bundel
et al., 2011; Massie et al., 2011) indicates that system x−c releases
L-glu into the extrasynaptic space and demonstrates that this
transporter is important in the regulation of extrasynaptic L-glu
levels. This is further supported by the observation that when
measured by in vivomicrodialysis, the rise in extrasynaptic L-glu
induced by EAAT inhibitors is neutralized by blocking system
x−c while blocking neuronal vesicular L-glu release is ineffective
(Baker et al., 2002; Melendez et al., 2005).
Taken together, glutamatergic neurotransmission not only
occurs via classical excitatory synapses but also via extrasynaptic
L-glu receptors (Figure 1). Moreover, the levels of extrasynaptic
L-glu are determined, at least in part, by glial non-vesicular L-glu
release (Figure 1). However, the regulation of extrasynaptic L-glu
levels as well as its temporal-spatial dynamics and its impact on
neuronal function, neurodegeneration, and behavior are far from
being fully understood.
Other Molecules that are Physiologically
Present in the Brain and May Activate
Glutamate Receptors
Very early studies indicated that L-asp, like L-glu, has an
excitatory action on neurons (Curtis et al., 1960). L-asp co-
localizes with L-glu in the synaptic vesicles of asymmetric
excitatory synapses (Gundersen et al., 1998). However, the
total concentration in the brain (0.96–1.62µmol/g wet weight)
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(Perry et al., 1971; Lefauconnier et al., 1976), the extracellular
concentrations in the cortex as measured by microdialysis
(1.62µM for L-asp and 9.06µM for L-glu) and its distribution as
determined by immunohistochemistry (Gundersen et al., 1991)
indicate that L-asp is less abundant that L-glu. However, L-asp is
a potent agonist on NMDA receptors but not other iGluRs with
an EC50 only eight-fold higher than that of L-glu (Patneau and
Mayer, 1990). EAATs that play an important role in the uptake
of vesicularly released L-glu in the CNS (Tanaka et al., 1997; Petr
et al., 2015) also avidly take up L-asp (Arriza et al., 1994). Thus, L-
asp is probably not as important as L-glu with respect to the total
excitatory tone mediated by iGluRs but must not be forgotten
in this context. In addition to its role as a neurotransmitter,
as mentioned above, L-asp is also required as a substrate for
aspartate amino transferase that converts 2-oxoglutarate to L-glu
for transport into the synaptic vesicles of glutamatergic neurons
(Takeda et al., 2012) and thus might indirectly increase L-glu
release.
One feature that distinguishes NMDA receptors from other
iGluRs is that activation of NMDA receptors requires the binding
of a co-agonist to the glycine binding site of the receptor (Johnson
and Ascher, 1987). Within the spinal cord and the retina, the
source of glycine might be spillover from glycinergic inhibitory
synapses (Ahmadi et al., 2003; Kalbaugh et al., 2009). However,
in other parts of the brain with high NMDA receptor expression,
like the hippocampal formation (Monyer et al., 1994), responses
mediated by strychnine-sensitive glycine receptors are absent, at
least in adult neurons, indicating the lack of glycinergic inhibitory
neurotransmission (Ito andCherubini, 1991). However, glycine is
present in the extracellular fluid in the hippocampus at baseline
levels of approximately 1.5µM (Yamamoto et al., 2010), which
is near the saturation of the glycine binding site of the NMDA
receptor (Johnson and Ascher, 1987), but can be dynamically
up- and down-regulated (Yamamoto et al., 2010). The source
of extracellular glycine in the hippocampus might be neurons,
which release glycine via the alanine-serine-cysteine amino acid
transporter 1 (asc-1; Rosenberg et al., 2013). However, glycine
release by astrocytes, which is stimulated by depolarization and
kainate, has also been reported (Holopainen and Kontro, 1989).
Even very early studies of the NMDA receptor and its co-
activation by glycine showed that D-amino acids, especially
D-serine, are almost as effective as glycine (Kleckner and
Dingledine, 1988). Only a few years later, it became apparent that
D-serine is present in rat and human brains at approximately
one third of the concentration of L-serine with an absolute
concentration of more that 0.2µmol/g brain tissue (Hashimoto
et al., 1992, 1993). Using an antiserum specific for D-serine,
Schell et al. demonstrated that D-serine in the brain is exclusively
localized in astrocytes and that its distribution matches the
expression of NMDA receptors (Schell et al., 1995). Moreover,
the same authors showed that D-serine is released from cultured
astrocytes upon exposure to L-glu or kainate (Schell et al.,
1995). The abundance of D-serine is determined by both the
degrading enzyme D-amino acid oxidase (DAO), which shows
high expression in the hindbrain, where D-serine levels are
low, and the synthetic enzyme serine racemase that generates
D-serine from L-serine (Schell et al., 1995; Wolosker et al.,
1999). D-Serine seems to be stored in cytoplasmic vesicles
in astrocytes and is released by exocytosis (Mothet et al.,
2005). Long-term potentiation depends on D-serine release
from astrocytes in hippocampal slices, indicating that this
amino acid indeed plays an important role in glutamatergic
neurotransmission via NMDA receptors (Henneberger et al.,
2010). Also in hippocampal slices, Papouin et al. determined,
using D-serine and glycine degrading enzymes, that D-serine
serves as a co-transmitter for synaptic NMDA receptors on CA1
neurons whereas glycine serves as the endogenous co-agonist
for extrasynaptic NMDA receptors (Papouin et al., 2012). This,
however, is not a general rule as synaptic NMDA receptors of
dentate gyrus neurons use glycine instead of D-serine as the
co-agonist (Le Bail et al., 2015).
Taken together, multilayered evidence suggests that not only
L-asp acting as an agonist on NMDA receptors but also glycine
as well as D-serine play important roles in glutamatergic
neurotransmission in the brain. However, other molecules have
also been proposed to be biologically relevant modulators of
glutamatergic neurotransmission.
L-homocysteate (L-HCA) shares structural similarities with
L-glu. This non-protein amino acid is an oxidation product of
homocysteine (Frauscher et al., 1995) which is biosynthesized
from methionine by the removal of its terminal methyl group
and is an intermediate of the transsulfuration pathway through
which methionine can be converted to cysteine via cystathionine
(McBean, 2012). Early studies showed that this amino acid can
induce calcium influx in cultured neurons as efficiently as L-glu
(Berdichevsky et al., 1983). Indeed, L-HCA showed a high affinity
for NMDA receptors as compared to other iGluRs in binding
assays which correlated with its ability to induce NMDA receptor
antagonist-inhibitable excitotoxicity and sodium influx (Pullan
et al., 1987). In addition, L-HCA is able to activate mGluR5 as
effectively as L-glu (Shi et al., 2003). L-HCA is present in the brain
although the concentrations were found to be about 500-fold
lower than those of L-glu and 100-fold lower than those of L-asp
in different areas of the rat brain (Kilpatrick and Mozley, 1986).
Upon potassium-induced stimulation, L-HCA release is induced
from brain slice preparations as observed for L-asp and L-glu
although the absolute release of HCA is about 50-fold lower (Do
et al., 1986). Interestingly, HCA is a highly effective competitive
inhibitor of cystine and L-glu uptake via the cystine/glutamate
antiporter system x−c (Bannai and Ishii, 1982; Patel et al., 2004),
the activity of which regulates the extracellular extrasynaptic L-
glu concentrations in the brain (De Bundel et al., 2011). Thus,
the effect of L-HCA on the activation of NMDA and other L-glu
receptors (Yuzaki and Connor, 1999) might also depend on the
L-HCA-induced release of L-glu via system x−c . In summary, L-
HCAmay only play a limited role in the overall stimulatory input
on L-glu receptors. However, this may change dramatically under
some conditions, e.g., in patients with high-dose methotrexate
therapy, an anticancer drug that, by inhibiting dihydrofolate
reductase, inhibits the tetrahydrofolate-catalyzed recycling of
methionine from homocysteine. Here, L-HCA concentrations of
more than 100µM have been documented in the cerebrospinal
fluid whereas L-HCA was undetectable in control subjects
(Quinn et al., 1997).
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FIGURE 2 | Kynurenine metabolism. By either
indoleamine-2,3-dioxygenase (IDO) or tryptophan-2,3-dioxygenase (TDO),
tryptophan is converted to N-formyl-L-kynurenine, which is metabolized to
L-kynurenine by formaminidase. L-kynurenine may be metabolized to
kynurenic acid by kynurenine aminotransferase (KAT), to
3-hydroxy-L-kynurenine by kynurenine-3-monooxygenase or to anthranilic
acid by kynureninase. 3-Hydroxy-L-kynurenine and anthranilic acid can both
be converted to 3-hydroxyanthranilic acid. 3-Hydroxyanthranilate oxidase
(3-HAO) metabolizes 3-hydroxyanthranilic acid to
2-amino-3-carboxymuconate-semialdehyde which is non-enzymatically
converted to quinolinic acid. Inhibition of KMO results in increased production
of kynurenic acid while the generation of quinolinic acid is inhibited (modified
from Vécsei et al., 2013).
Additional endogenous small molecules that are thought
to interfere with L-glu signaling are several intermediates of
tryptophan metabolism (Vécsei et al., 2013; Figure 2). Via the
action of indoleamine 2,3-dioxygenase (IDO) or tryptophan
2,3-dioxygenase (TDO), tryptophan is converted to N-formyl-
L-kynurenine, which is then converted to kynurenine (KYN)
by formamidase. From here three pathways, two of which
merge at a later step, lead to further metabolism. First, via
the action of kynurenine aminotransferase (KAT), KYN is
converted to kynurenic acid (KYNA). KYN also can be converted
to 3-hydroxykynurenine (3HK) by kynurenine monooxygenase
(KMO), which can then be used as a substrate by kynureninase
for the synthesis of 3-hydroxyanthranilic acid (3HANA). In
addition, using KYN as a substrate, kynureninase produces
anthranilic acid (ANA), which by non-specific hydroxylation can
also be converted to 3HANA. 3HANA finally serves a substrate
for the generation of quinolinic acid (QUIN).
The tryptophan concentration in rat brain is about 25 nmol/g
wet weight and thus about 400-fold less than L-glu and 100-fold
less than L-asp (Gál and Sherman, 1978; Kilpatrick and Mozley,
1986). The reported brain concentrations of kynurenines are
even lower with 0.4–1.6 nmol/g for QUIN (Wolfensberger et al.,
1983), 0.01–0.07 nmol/ml for KYNA (Moroni et al., 1988), and
0.016 nmol/g for 3HANA (Baran and Schwarcz, 1990). About
40% of brain KYN is locally synthesized (Gál and Sherman,
1978). The different metabolites of tryptophan show differential
binding to plasma proteins and their transport via the blood-
brain barrier is very different. KYN and 3HK are transported
via the large neutral amino acid carrier system L (Fukui et al.,
1991). Other kynurenines seem to enter the brain by passive
diffusion. In addition, ANA, 3HANA and especially KYNA avidly
bind to serum proteins, which limit their diffusibility across the
blood-brain barrier.
As early as 1982, it was found that QUIN, when
ionophoretically applied to rat cortex, induced neuronal
firing that was inhibited by an NMDA receptor antagonist
(Birley et al., 1982), indicating that QUIN may act as an NMDA
receptor agonist. However, the EC50 for QUIN to activate
NMDA receptor currents has been shown to be approximately
1000-fold higher than the EC50 of L-glu (Patneau and Mayer,
1990). Of note, intracerebral injection of QUIN has been
shown to induce ultrastructural, neurochemical, and behavioral
changes very similar to those induced by NMDA receptor
agonists (Schwarcz et al., 1983). However, the fact that QUIN
concentrations are about 5000- to 15,000-fold lower than
cerebral L-glu concentrations makes it highly unlikely that
modulation of NMDA receptor signaling by QUIN plays a
significant role. KYNA was reported to act as an NMDA receptor
antagonist (Ganong et al., 1983; Ganong and Cotman, 1986).
However, although infusion with the KMO inhibitor Ro 61-8048
increased cerebral extracellular KYNA concentrations 10-fold,
this did not lead to an inhibition of NMDA-mediated neuronal
depolarization, a finding that challenges the notion that KYNA
at near physiological levels directly modulates NMDA receptors
(Urenjak and Obrenovitch, 2000). In contrast, increased KYNA
in the brain induced by the KMO inhibitor JM6 decreased the
extracellular cerebral L-glu concentration (Zwilling et al., 2011).
In addition, KYNA levels in the extracellular cerebral fluid highly
correlated with L-glu levels indicating that even at physiological
or near physiological levels KYNA modulates L-glu metabolism
(Zwilling et al., 2011). Both activation of the G-protein-coupled
receptor GPR35 (Berlinguer-Palmini et al., 2013) and inhibition
of presynaptic α7 nicotinic acetylcholine receptors have been
implicated in the KYNA-induced reduction in L-glu release
(Carpenedo et al., 2001). To summarize, although L-HCA and
QUIN are present in the brain, their low concentrations speak
against them having prominent roles in regulating glutamatergic
neurotransmission. In contrast, although the pathways still have
to be defined in more detail, evidence supports the view that
KYNA can modulate L-glu release and thereby L-glu levels and
neurotransmission.
THE CONCEPTS OF ACUTE AND
CHRONIC GLUTAMATE TOXICITY
The term excitotoxicity was first used by Olney (1986) to
describe the ability of L-glu, as well as structurally related amino
acids, to kill nerve cells, a process that has been proposed
to take place not only in acute but also chronic diseases of
the central nervous system (for reviews Choi, 1988; Meldrum
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and Garthwaite, 1990). Excitotoxicity results from the excessive
activation of iGluRs and leads to a characteristic loss of post-
synaptic structures including dendrites and cell bodies. There
is a significant level of variation in the sensitivity of different
nerve cells to the various iGluR agonists which is related to
both the specific receptors expressed on the nerve cells as
well as their distinct metabolisms. Moreover, the susceptibility
of neurons to excitotoxicity can change tremendously with
age. Acute excitotoxic nerve cell death is thought to occur
in response to a variety of severe insults including cerebral
ischemia, traumatic brain injury (TBI), hypoglycemia, and status
epilepticus (Meldrum and Garthwaite, 1990; Meldrum, 1994).
But what about neurodegenerative diseases where nerve cell
death occurs over an extended period of time? Does chronic
excitotoxicity also exist? In other words, could exposure of
nerve cells to low but above normal concentrations of L-glu
(or glutamatergic neurotransmission as a sum of the input
via the various molecules involved as discussed above) over
an extended period of time also eventually lead to nerve cell
death?
Excitotoxicity was originally studied in animals but in order
to understand the mechanisms underlying this process, cell
culture models were developed (for review Choi, 1988). The
basic cell culture model of acute excitotoxicity involves treating
primary neurons in culture with L-glu or a specific iGluR agonist
for a short time period (min) (e.g., Choi, 1992; Schubert and
Piasecki, 2001) and then assessing downstream events at the
time point that is most relevant for the study. For example,
cell death is often determined after 24 h. While these types of
studies have been shown to be very useful for understanding the
pathways involved in acute excitotoxicity, it has proven much
more difficult to study chronic excitotoxicity in culture partly
because it is not entirely clear how to define “chronic” in the
context of cell culture. Does chronic mean a low dose given for
24 h rather than a higher dose given for 5–10min or is it more
complicated than that? In one of the few studies that attempted
to develop a model of chronic excitotoxicity (Ha et al., 2009), it
was shown that it is indeed more complicated with acute and
chronic excitotoxicity appearing to be distinct processes. In this
study, the authors used pure cultures of primary cortical neurons
prepared from day 14 mouse embryos and treated them after
7 and 14 days in culture (DIV; Ha et al., 2009). For chronic
excitotoxicity, the neurons were exposed to L-glu or NMDA
for 24 h and for acute excitotoxicity for 10min. In both cases,
cell death was measured after 24 h. Surprisingly, the EC50s for
the toxicity of L-glu were lower for acute toxicity, especially
in the 7DIV cultures, as compared to the EC50s for chronic
toxicity. In addition, it was found that a high cell culture density
increased the sensitivity of the cells to acute but not chronic
excitotoxicity. Further studies suggested that the lower sensitivity
of the neurons to L-glu in the chronic excitotoxicity paradigm
was due to the activation of mGluR1, consistent with earlier data
on the neuroprotective effects of mGluR1 activation (Sagara and
Schubert, 1998).
An alternative approach to studying chronic glutamate
toxicity utilized organotypic spinal cord cultures in combination
with L-glu uptake inhibitors (Rothstein et al., 1993). These spinal
cord cultures, which were prepared from 8-day-old rat pups, can
be maintained in culture for up to 3 months. Chronic inhibition
of L-glu uptake with two different uptake inhibitors resulted in a
persistent elevation of L-glu in the cell culture medium and time-
and concentration-dependent motor neuron cell death. The
highest concentration of uptake inhibitor increased extracellular
L-glu levels at least 25-fold and began to kill the cells within 1
week whereas a five-fold lower concentration raised extracellular
L-glu levels eight-fold and cell death only began after 2–3 weeks
of treatment. The toxicity was blocked by non-NMDA but
not NMDA receptor antagonists as well as by inhibitors of L-
glu synthesis or release. These experiments suggest that even
moderately increased L-glu concentrations can induce toxicity.
In vivo approaches to studying chronic excitotoxicity have
mainly relied on an approach analogous to that used with
the spinal cord cultures. In the majority of these studies, one
or more EAATs were transiently or permanently genetically
eliminated and the effects on brain function examined. In the
first of these studies that used rats (Rothstein et al., 1996),
chronic intraventricular administration of antisense RNA was
used to eliminate each of the three main EAATs (EAAT1, EAAT2,
and EAAT3). The loss of either of the glial L-glu transporters
(EAAT1 and EAAT2) but not the neuronal transporter (EAAT3)
resulted in large increases in extracellular L-glu concentrations
in the striatum after 7 days as determined by microdialysis
(EAAT2, 32-fold increase; EAAT1, 13-fold increase). Treatment
with either the EAAT1 or EAAT2 antisense oligonucleotides
caused a progressive motor impairment whereas the EAAT3
antisense oligonucleotide mainly produced epilepsy. The loss
of any of the three transporters produced clear evidence of
neuronal damage in the striatum and hippocampus after 7 days
of treatment although the effects of the EAAT1 and EAAT2
antisense oligonucleotides were much more dramatic, consistent
with the large increases in extracellular L-glu brought about by
treatment with these antisense oligonucleotides.
Quite different results were obtained with homozygous mice
deficient in EAAT2 (Tanaka et al., 1997) or EAAT1 (Watase
et al., 1998). Mice deficient in EAAT2 displayed spontaneous
and generally lethal seizures with 50% dead by 6 weeks of
age (Tanaka et al., 1997). Approximately 30% of the mice
showed selective neuronal degeneration in the hippocampal CA1
region at 4–8 weeks of age. L-glu levels in the CA1 region
of the hippocampus measured by microdialysis were ∼three-
fold higher in the mutant mice as compared with the wild
type mice (Mitani and Tanaka, 2003). In contrast, heterozygous
EAAT2 knock-out mice have a normal lifespan and do not
show hippocampal CA1 atrophy (Kiryk et al., 2008). However,
they display some behavioral abnormalities suggestive of mild
glutaminergic hyperactivity. While mice deficient in EAAT1,
which is highly expressed in cerebellar astrocytes, did not show
changes in cerebellar structure or obvious symptoms of cerebellar
impairment such as ataxic gait, they were unable to adapt to more
challenging motor tasks such as quickly running on the rotorod
(Watase et al., 1998). Taken together, these results suggest that
disruptions in glutamatergic homeostasis have a much greater
impact when they occur in the adult animal rather than when
they are present from conception.
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Tuberous sclerosis complex (TSC) is a multi-system genetic
disease caused by mutation of either the TSC1 or TSC2 genes
and characterized by severe neurological symptoms. Mice with
inactivation of the TSC1 gene in glia have a >75% decrease in
the expression and function of EAAT1 and EAAT2 and develop
seizures (Zeng et al., 2007). At 4 weeks of age, prior to the
development of seizures in these mice, there was an ∼50%
increase in extracellular L-glu in the hippocampus of these
mutant mice, as determined by microdialysis, which correlated
with increases in markers of cell death in neurons in both the
hippocampus and cortex. Using hippocampal slices from 2 to
4 week old mice, impairments in long-term potentiation were
identified, which translated into functional deficits when juvenile
mice were tested for spatial and contextual memory in theMorris
water maze and fear conditioning assays, respectively.
In most of the studies described above, there was a large
increase in extracellular L-glu which, when examined, led, in
most cases to negative impacts on the function of specific
neuronal populations. To determine the long-term effects of
more moderate increases in extracellular glutamate, Bao et al.
(2009) created transgenic (Tg) mice with extra copies of the
gene for Glud1 specifically in neurons. The GLUD1 protein is
a mitochondrial enzyme that converts L-glu to 2-oxoglutarate.
Mitochondrial 2-oxoglutarate is transported to the cytoplasm
of nerve terminals where it is converted back into L-glu and
stored in synaptic vesicles thereby contributing to the pool of
synaptically releasable L-glu (Palaiologos et al., 1988; Takeda
et al., 2012). Nine month old Glud1 Tg mice showed an ∼10%
increase in L-glu in the hippocampus and striatum relative to wild
type mice as determined using magnetic resonance spectroscopy.
In addition, evoked L-glu release in the striatum was increased
by ∼50%. At 12–20 months of age, the Glud1 Tg mice showed
significant decreases in the numbers of neurons in the CA1
region of the hippocampus and granule cell layer of the dentate
gyrus as well as an age-dependent loss of both dendrites and
dendritic spines in the hippocampus. There was also a decrease
in long-term potentiation following high frequency stimulation
in hippocampal slices from the Tg mice as compared to the
wild type mice. However, whether these alterations resulted
in behavioral impairments was not examined. Analysis of the
transcriptome of the Glud1 Tg mice as compared to wild type
mice suggested that long-termmoderate increases in extracellular
L-glu result in both accelerated aging at the level of gene
expression coupled with compensatory responses that protected
against stress and/or promoted recovery (Wang et al., 2010).
In summary, increases in extracellular L-glu in vivo can affect
nerve cell survival and brain function. The consequences seem
to be highly dependent on the degree of L-glu increase but
even a 10% increase appears to affect nerve cell structure and
survival particularly in the context of aging suggesting that
chronic excitotoxicity may be particularly relevant to age-related
neurodegenerative diseases.
Plant-based toxins have provided additional evidence for
chronic excitotoxicity. These include domoic acid, the cause
of amnesiac shellfish poisoning, from the alga Pseudo-nitzschia
(Grant et al., 2010), β-N-oxalylamino-L-alanine (BOAA), the
cause of lathyrism, from the plant Lathyrus sativus (Ludolph
and Spencer, 1995) and possibly β-N-methylamino-L-alanine
(BMAA), a postulated cause of Guamian amyotrophic lateral
sclerosis/Parkinson-dementia complex (ALS/PDC), from the
cycad Cycas circinalis (Karamyan and Speth, 2008). Based on
evidence from human, and in some cases animal, exposures that
resulted in significant neurological damage, further studies on
these toxins showed that they all act on L-glu receptors and
induce both acute and chronic neurotoxicity.
Domoic acid binds with high affinity to AMPA-, kainate-,
and NMDA-type iGluRs (Qiu et al., 2006). Both acute, high-
dose toxicity, which can include seizures and death as well as
lower dose, chronic toxicity of domoic acid have been described
in both humans and animals that consumed shellfish and other
sea life that eat the alga and concentrate the toxin (Grant et al.,
2010). Domoic acid-related neuropathology occurs mainly in
the hippocampus and results in memory deficits which may
be permanent (Grant et al., 2010). Studies in animals suggest
that domoic acid toxicity can be progressive over time with
a significant period of good health after exposure before the
manifestation of delayed injury (Grant et al., 2010).Moreover, the
toxicity appears to be exacerbated by increasing age (Qiu et al.,
2006).
Lathyrism is a neurological condition that develops only after
several months of ingestion of the grass pea and only when it
constitutes at least 30% of a nutritionally-poor diet (Paleacu et al.,
1999). BOAA binds preferentially to non-NMDA-type iGluR.
In contrast to domoic acid, BOAA specifically and selectively
targets the upper motor neurons resulting in spastic paraparesis
(Ludolph and Spencer, 1995). Lathyrism is not associated with
any cognitive problems (Paleacu et al., 1999).
BMAA, which is closely related to BOAA, binds to both
NMDA-type and non-NMDA-type iGluRs (Lobner et al., 2007).
In addition, it can both inhibit cystine uptake into cells via
system x−c thereby promoting oxidative stress and, as it is a
substrate inhibitor, promote L-glu release from cells via the same
transporter, which can enhance excitotoxicity through activation
of mGluR5 (Liu et al., 2009). While the evidence that it could
be responsible for Guanamian ALS/PDC is still debatable after
almost 50 years (Karamyan and Speth, 2008), oral administration
of BMAA to macaques dose-dependently caused a motor system
disorder with involvement of both the upper and lower motor
neurons as well as the extrapyramidal system after 2–12 weeks
of treatment (Spencer et al., 1987). Histological examination
showed that the motor cortex was most affected followed by
the spinal cord and then the substantia nigra, which was mostly
spared. While these symptoms resembled the early stages of
Guanamian ALS/PDC, the severe cognitive deficits associated
with the disorder were not seen. However, this could be related
to the relatively short treatment period, the relatively young age
of the macaques and/or the nutritional adequacy of their diet.
In summary, several toxins that bind to iGluRs and have
been shown to induce excitotoxicity in cell culture can cause
slowly developing neurological problems in both humans and
animals. Interestingly, each toxin appears to target a specific
type of neuron, an effect that might be related to both the
pharmacokinetic and ADME properties of the toxins, which have
not yet been studied to any great extent. However, the data from
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these toxins supports the idea that chronic excitotoxicity exists in
humans and could play a role in multiple neurological disorders.
Since iGluRs are found both in the synapse as well in
extra-synaptic locations, there has been a great deal of effort
devoted to determining if the location of the receptors impacts
the toxicity of glutamate and related molecules. An influential
study using primary neuronal cultures (Hardingham et al., 2002)
suggested that synaptic and extrasynaptic NMDA receptors have
counteracting effects on cell fate with nerve cell death being
mainly mediated by extrasynaptic NMDA receptors. However,
these results have not been reproduced in brain slices or
in vivo (reviewed in Papouin and Oliet, 2014). Furthermore,
several more recent studies using the same primary neuronal
culture preparation protocol as the earlier study found either no
difference between synaptic and extrasynaptic NMDA receptors
in promoting excitotoxicity (reviewed in Papouin and Oliet,
2014) or found that both receptors were required for cell
death (Zhou et al., 2013). Moreover, a number of studies that
supported the idea that extrasynaptic NMDA receptors promote
excitotoxicity relied on the NMDA receptor inhibitor memantine
which was originally thought to specifically act on extrasynaptic
NMDA receptors (Xia et al., 2010). However, more recent studies
have shown that memantine can inhibit both synaptic and
extrasynaptic NMDA receptors (Emnett et al., 2013). Together
these results strongly suggest that both synaptic and extrasynaptic
NMDA receptors can contribute to excitotoxicity but that the
precise contribution of each may depend on the experimental
and/or pathological conditions.
EVIDENCE FOR GLUTAMATE
DYSREGULATION AND EXCITOTOXICITY
IN DIFFERENT NEURODEGENERATIVE
DISEASES
Excitotoxicity in Acute Diseases of the CNS
As mentioned above, excitotoxicity was initially defined as
an acute insult to nerve cells that leads to cell death by
excessive activation of iGluRs. Acute excitotoxicity is known
to play an important role in specific CNS disorders including
cerebral ischemia, TBI, and status epilepticus. However, the
mechanisms underlying acute excitotoxicity differ slightly among
these different disorders as described below.
During brain ischemia, the initiation of L-glu- (or L-asp-)
mediated excitotoxicity occurs within minutes due to the rapid
increase in extracellular cerebral L-glu (and L-asp; reviewed in
Dirnagl et al., 1999). The sudden loss of the energy supply
due to the shut down of blood flow to the brain leads to a
breakdown of the neuronal and astroglial membrane potentials
as the maintenance of these is energy-dependent. In neurons,
the subsequent membrane depolarization leads to vesicular L-
glu release. In addition, energy depletion and disruption of ionic
homeostasis inhibits EAAT activity in astrocytes and may even
induce a reversal in their action thereby leading to non-vesicular
L-glu and L-asp release. The release of L-glu/L-asp (Graham
et al., 1990) from these different sources leads to excitotoxicity,
mostly by over-activation of iGluRs of the NMDA type as shown
by the efficacy of NMDA antagonists in the acute phase in
animal models of transient cerebral ischemia (Park et al., 1988;
Bielenberg and Beck, 1991; Katsuta et al., 1995).
In TBI, the mechanical tissue damage and disruption of
the blood-brain barrier is the initiator of acute secondary
neurodegeneration, which, in addition to neuroinflammation
and oxidative stress, is mediated by L-glu release from
intracellular compartments and thus by acute excitotoxicity
(reviewed in Freire, 2012). Accordingly, acute administration
of the NMDA antagonist MK801 following TBI ameliorates
neuronal loss and long-term behavioral abnormalities (Sönmez
et al., 2015).
In status epilepticus, ongoing synchronized activity of
excitatory neuronal networks with concurrent breakdown of
inhibitory mechanisms is the primary source of increased L-
glu (and L-asp) release. As the intensity of synchronous activity
is dependent on the integration of a nerve cell into a specific
neuronal network and the ability of a nerve cell to withstand
excessive glutamatergic input depends, among other properties,
on the expression pattern of iGluRs, a rather restricted and
maturation-dependent degeneration of neuronal populations is
induced by prolonged epileptic seizures (Sankar et al., 1998). The
relevance of excitotoxicity in status epilepticus is demonstrated
by the fact that NMDA antagonists like ketamine reduce neuronal
loss (Loss et al., 2012).
Chronic Excitotoxicity during Progressive
Long-Term Neurodegeneration
As compared to acute insults to the CNS, in chronic
neurodegenerative diseases the situation is much more complex.
First, although compromised mitochondrial function has been
repeatedly described in several neurodegenerative diseases
(reviewed in Johri and Beal, 2012), the resulting impairments
in energy supply are not nearly as severe as the energy
failure in ischemic stroke. Thus, if excitotoxicity contributes
to neurodegeneration, a very different time course of chronic
excitotoxicity has to be assumed. In the following paragraphs,
we will summarize what is known about the different pathways
that might contribute to excitotoxicity in neurodegenerative
diseases. We will focus on amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease (AD) and Huntington’s disease (HD) as
important examples with sufficiently validated animal models.
Amyotrophic Lateral Sclerosis
ALS is a neurodegenerative disease where the degeneration
of motor neurons dominates the clinical presentation and the
course of the disease, which is fatal within a few years from onset.
It is hypothesized that L-glu excitotoxicity plays a role in the
motor neuron death in ALS as these cells express high levels of
calcium-permeable AMPA receptors (Carriedo et al., 1996) and
low levels of calcium binding proteins (Leal and Gomes, 2015).
In contrast to the application of AMPA and kainate, as well as L-
HCA, to the lumbar spinal cord of rats, treatment with NMDA
spared motor neurons, indicating that NMDA excitotoxicity
might not play a prominent role in ALS (Ikonomidou et al.,
1996). However, NMDA receptor-mediated excitotoxicity in
motor neurons was documented in chick embryo organotypic
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slice cultures (Brunet et al., 2009). Electrophysiological studies
indicated that there is a transient hyperexcitability of motor
neurons in the presymptomatic stage of ALS in mice transgenic
for the G93A mutation of human SOD1 that is associated
with hereditary ALS (Fuchs et al., 2013). In addition, a cortical
hyperexcitability has been documented in familial and sporadic
ALS patients that precedes the onset of clinical symptoms in
familial ALS mutation carriers (Vucic et al., 2008). Finally, the
only approved drug to treat ALS, which increases survival by
2–3 months (Miller et al., 2012), acts as an inhibitor of NMDA
and kainate receptors (Debono et al., 1993) as well as rapidly
upregulating EAAT activity in synaptosomes (Azbill et al., 2000).
In autopsied spinal cord from patients with ALS, several
groups reported a pronounced reduction of EAAT2 but not
EAAT1 protein expression in the gray matter in areas with
significant motor neuron loss (Sasaki et al., 2000). In addition,
both L-glu uptake as well as EAAT2 immunoreactivity, as
analyzed by Western blotting, were shown to be quantitatively
reduced in postmortem tissue of ALS patients especially in
the spinal cord, the tissue that is most affected by the disease
(Rothstein et al., 1992; Lin et al., 1998). Moreover, it was reported
that as a potential consequence of EAAT2 downregulation, L-glu
levels are increased in the CSF in patients with ALS (Rothstein
et al., 1990). However, this finding could not be replicated by
others (Perry et al., 1990).
The downregulation of EAAT2 in human ALS is recapitulated
in several animal models of ALS including transgenic mice
expressing human SOD1 containing the G93A mutation that
causes hereditary ALS (Bendotti et al., 2001) or transgenic
rats expressing the same mutation (Howland et al., 2002).
Interestingly, whereas Bendotti found a late decrease in EAAT2
expression at the time when the mice have already become
symptomatic (Bendotti et al., 2001), Howland et al. reported
changes in EAAT2 expression in the presymptomatic stage
(Howland et al., 2002). The β-lactam antibiotic ceftriaxone (Cef)
induces EAAT2 in cultured murine spinal cord slices (Rothstein
et al., 2005) and in neuron/astrocyte co-cultures (Lewerenz et al.,
2009). It also induced EAAT2 expression in the spinal cords
of wild-type and mutant G93A mSOD1 Tg mice, which was
associated with a decrease in motor neuron loss, weight loss, and
other ALS-like symptoms and an increase in survival (Rothstein
et al., 2005), compatible with the idea that EAAT2 loss contributes
to chronic excitotoxicity in this mouse model. Just recently, a
prominent reduction in EAAT2 immunoreactivity was reported
in an independent rodent model for ALS, rats expressing ALS-
inducing mutant TAR DNA binding protein 43 in astrocytes
only (Tong et al., 2013). Interestingly, Alexander et al. found
that, when measured by microdialysis, the extracellular L-glu
and L-asp concentrations are increased and the L-glu clearance
capacity is decreased in the cerebral cortex of G93A mSOD1
Tg mice although this area does not show overt pathology nor
downregulation of EAAT1 and 2 when analyzed by Western
blotting (Alexander et al., 2000).
Taken together these publications support the view that there
is a downregulation of EAAT2 in both human ALS patients
and animal models of ALS. However, while some animal studies
suggest that EAAT2 downregulation occurs prior to motor
neuron loss, others are compatible with the hypothesis that the
downregulation of EAAT2, the astroglial expression of which
depends on the presence of neurons (Morel et al., 2013), is a
consequence of neuronal degeneration.
Whereas, EAATs decrease extracellular L-glu, extracellular
cerebral L-glu is upregulated in different brain regions by the
cystine/glutamate antiporter system x−c (De Bundel et al., 2011;
Massie et al., 2011). xCT, the specific subunit of system x−c , was
reported to be differentially regulated in mouse models of ALS.
Albano et al. (2013) reported that the uptake of radiolabelled
cystine was upregulated in spinal cord slices of presymptomatic
G93A mSOD1 Tg mice at the age of 70 days but not at 55 or 100
days and not in symptomatic 130 day-old mice and confirmed
that the upregulation of cystine uptake at day 70 was due to
system x−c activity using the system x
−
c inhibitor sulfasalazine
(SSZ). It has to be kept in mind, however, that cystine can
also be transported by EAATs (Hayes et al., 2005). Thus, as
data about the SSZ-sensitivity of the cystine uptake were not
presented for days 100 and 130, the lack of differential cystine
uptake found in this study at the older ages might rather be
a consequence of decreased EAAT activity. In contrast, Mesci
et al. (2015) using rtPCR, demonstrated a robust increase in
xCT mRNA levels in G37R mSOD1 Tg mice upon the onset of
symptoms, which was further increased as symptoms progressed
(Mesci et al., 2015). Moreover, it was demonstrated that xCT
was predominantly expressed in spinal cord microglia. When
acutely purified from spinal cord, microglia already showed
xCT mRNA upregulation in the presymptomatic phase. Taken
together, these findings indicate that system x−c is upregulated
in animal models of ALS. However, evidence is lacking about
whether this is also true for human cases of ALS. Nevertheless,
Mesci demonstrated that the mRNA levels of CD68, a marker of
microglial activation, correlated with xCT mRNA expression in
postmortem spinal cord tissue of patients with ALS, suggesting
that neuroinflammation in humans is associated with xCT
upregulation (Mesci et al., 2015).
Beyond the dysregulation of L-glu and L-asp levels by
EAAT downregulation or system x−c upregulation, pathways that
indirectly modulate glutamatergic neurotransmission have also
been proposed to be involved in motor neuron degeneration
in ALS. D-Serine levels have been shown to be progressively
increased in the spinal cord of G93A mSOD1 Tg mice (Sasabe
et al., 2007, 2012). Beginning at disease onset and continuing
during the course of the symptomatic phase, D-serine augments
NMDA excitotoxicity in motor neurons (Sasabe et al., 2007,
2012). The upregulation of D-serine in the spinal cord was
replicated by others (Thompson et al., 2012). Downregulation
of the D-serine metabolizing enzyme DAO in the reticulospinal
tract was identified as the main mechanism for D-serine
upregulation in the spinal cord in ALS mice (Sasabe et al., 2012).
In addition, genetic inactivation of DAO in mice leads to motor
neuron degeneration (Sasabe et al., 2012) and a deficiency in the
D-serine generating enzyme serine racemase prolonged survival
in G93A mSOD1 Tg mice although it paradoxically hastened
disease onset (Thompson et al., 2012). A heterozygous mutation
of DAO has been shown to segregate with the ALS phenotype
in a large family with hereditary ALS (Mitchell et al., 2010).
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FIGURE 3 | Potential mechanisms that lead to excitotoxicity in ALS.
EAAT2 downregulation and upregulation of system x−c cause increased
activation of glutamate receptors. Moreover, signaling via NMDA receptors is
potentiated by the upregulation of the co-activator D-serine.
However, this remains the only family identified so far where a
DAO mutation may be linked to the disease (Millecamps et al.,
2010).
Regarding the other amino acid co-agonist of the NMDA
receptor, glycine, an increase in the CSF levels in patients with
ALS was reported by one group (de Belleroche et al., 1984) but
could not be replicated by others (Perry et al., 1990; Rothstein
et al., 1990). Ilzecka reported that KYNA levels are upregulated
in the CSF of bulbar ALS patients and those in end stage
disease (Ilzecka et al., 2003). Independently, it was described
that tryptophan and KYN levels are increased in the CSF from
ALS patients as compared to controls (Chen et al., 2010). In
addition, IDOwas shown to be expressed in spinal cordmicroglia
and neurons from patients with ALS, indicating that microglial
activation could increase the conversion of tryptophan to KYN
in ALS.
In summary, multilayered evidence suggests that increased
glutamatergic neurotransmission is present in ALS and might
contribute to neurodegeneration (Figure 3). Downregulation of
EAAT2 in astrocytes and upregulation of system x−c in the
context of microglial activation has been repeatedly documented.
Increased co-activation of NMDA receptors by D-serine might
also play a role in glutamatergic dysregulation. In addition, the
kynurenine pathway seems to be activated in ALS, most likely in
the setting of neuroinflammation.
Alzheimer’s Disease
AD is the leading cause of dementia in the aging population.
Neuropathologically, AD is defined by neurodegeneration
with the presence of extracellular senile plaques consisting
of β amyloid (Aβ) and intraneuronal neurofibrillary tangles
consisting of aggregated tau (Grundke-Iqbal et al., 1986;
Ingelsson et al., 2004), which first appear in the hippocampus
and then spread as the disease progresses. Prominent microglial
activation is also a hallmark of AD. Hereditary forms of AD are
caused by mutations in the Aβ precursor protein, AβPP, or in the
presenilins, which are part of the multi-protein complex involved
in Aβ generation (Ringman et al., 2014). The pathophysiology
of AD is complex and many pathways are involved in the
synaptic and cellular degeneration in AD including abnormalies
in signaling pathways via glycogen synthase kinase-3 beta or
mitogen-activated protein kinases, cell cycle re-enty (reviewed
by Majd et al., 2015), oxidative stress (reviewed by Niedzielska
et al., 2015), or decreased transport of trophic factors and
mitochondrial dysregulation (reviewed by Overk and Masliah,
2014). However, multiple lines of evidence suggest that L-glu
dysregulation also plays a role in AD.
Grilli et al. showed that primary neurons from transgenic
mice overexpressing mutant presenilin are more sensitive to
excitotoxic stimuli in vitro (Grilli et al., 2000). In vitro, aggregated
Aβ enhances both NMDA and kainate receptor-mediated L-
glu toxicity, most likely by interfering with neuronal calcium
homeostasis (Mattson et al., 1992). Others have shown that
Aβ can increase neuronal excitability by impairing the ability
of glycogen synthase kinase 3β inhibition to reduce NMDA
receptor-mediated currents (Deng et al., 2014). Moreover, soluble
Aβ oligomers were found to induce L-glu release from astrocytes
eventually leading to dendritic spine loss via over-activation
of extrasynaptic NMDA receptors (Talantova et al., 2013).
Extracellular L-glu concentrations were found to be increased
in a triple transgenic mouse model of AD, in which a 3-month
treatment with the NMDA receptor inhibitor NitroMemantine
rescued synapse loss (Talantova et al., 2013).
A number of mouse studies have shown impacts of AD-
like pathology on EAAT expression and/or function. In acute
hippocampal slice preparations, Aβ was reported to inhibit the
clearance of synaptically released L-glu by decreasing membrane
insertion of EAAT2, an effect probably mediated by oxidative
stress (Scimemi et al., 2013). In aged AβPP23 mice, Schallier
et al. observed the downregulation of EAAT2 expression in the
frontal cortex and hippocampus, which in the frontal cortex
was associated with an increase in xCT expression (Schallier
et al., 2011). These changes were associated with a strong
tendency toward increased extracellular L-glu levels as measured
by microdialysis (Schallier et al., 2011). In triple transgenic AD
mice expressing the amyloid precursor protein mutations K670N
and M671L, the presenilin 1 mutation M146V and the tau
P301L mutation (Oddo et al., 2003; Zumkehr et al., 2015), a
strong and age-dependent reduction of EAAT2 expression was
found (Zumkehr et al., 2015). Restoration of EAAT2 activity in
these AD mice following treatment with the β-lactam antibiotic
Cef was associated with a decrease in cognitive impairment
as well as reduced tau pathology (Zumkehr et al., 2015). In
human AD brains, decreased expression of EAAT2 protein as
well as a decrease in EAAT activity was described (Li et al.,
1997). However, this finding could not be replicated by others
(Beckstrøm et al., 1999). Of note, on the transcriptome level,
Scott et al. found exon-skipping splice variants of EAAT2 that
decrease glutamate transport activity to be upregulated in human
AD brains (Scott et al., 2011). In the CSF, some groups found
an increase in glutamate concentrations (Pomara et al., 1992;
Csernansky et al., 1996; Jimenez-Jimenez et al., 1998; Kaiser et al.,
2010) in AD patients, whereas others found no change or even
decreased levels (Basun et al., 1990; Martinez et al., 1993; Kuiper
et al., 2000).
In vitro, Aβ induces L-glu release from primary microglia via
upregulation of system x−c (Qin et al., 2006). Other found that it
also induced L-glu release from astrocytes via activation of the
α7 nicotinic acetylcholine receptor (Talantova et al., 2013). In
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FIGURE 4 | Potential mechanisms that lead to excitotoxicity in AD.
Altered calcium homeostasis and increased sensitization of NMDA receptors in
AD renders neurons more sensitive to excitotoxicity. This is further amplified by
the upregulation of extracellular glutamate via downregulation of EAAT2 and
upregulation of system x−c .
addition, xCT, the specific subunit of system x−c is upregulated
in the vicinity of senile plaques, probably in microglia, in
Thy1-APP751 mice (TgAPP) expressing human APP bearing the
Swedish (S: KM595/596NL) and London (L: V6421) mutations as
well as after Aβ injection in the hippocampus (Qin et al., 2006).
Semiquantitative immunoblot analysis revealed an upregulation
of xCT protein expression in the frontal cortex in aged AβPP23
mice compared to wild-type controls (Schallier et al., 2011).
Postmortem studies indicate that KYN metabolism might
also be modified in AD as increased concentrations of KYNA
were found in the basal ganglia of AD patients (Baran et al.,
1999). Using immunohistochemistry, Guillemin et al. found
immunoreactivity for both IDO and QUIN upregulated in AD
brains, especially in the vicinity of plaques (Guillemin et al.,
2005). Of note, Aβ induces IDO expression in human primary
macrophages and microglia (Guillemin et al., 2003). Indeed,
systemic inhibition of KMO lead to increases in brain KYNA
levels and ameliorated the phenotype of a mouse model of AD
(Zwilling et al., 2011), indicating that an upregulation of KYNA
might be an endogenous protective response. Also the IDO
inhibitor, coptisine, reduced microglial, and astrocytic activation
and cognitive impairment in AD mice (Yu et al., 2015).
Taken together, along with several other detrimental changes,
there is evidence for chronic excitotoxicity in AD which may
be driven by multiple factors including the sensitization of
NMDA receptors, a decrease in L-glu and L-asp reuptake capacity
and an increase in glutamate release via system x−c (Figure 4).
Although the KYN pathway seems to be upregulated in AD,
no specific conclusions can be drawn regarding glutamatergic
neurotransmission from the reported upregulation of both
neurotoxic QUIN and neuroprotective KYNA.
Huntington’s Disease
HD is a dominantly inherited, fatal neurodegenerative disease
caused by a trinucleotide (CAG) repeat expansion in the coding
region of the huntingtin (htt) gene that leads to the degeneration
of GABAergic medium-sized spiny neurons (MSN) in the
striatum, although other brain regions are also affected as the
disease progresses. HD presents as a movement disorder with
co-morbid psychiatric and cognitive symptomatology (Nance,
1997). Both mutant htt RNA and the encoded protein that
contains a polyglutamine repeat expansion are thought to lead
to complex alterations in cellular metabolism culminating in
mitochondrial dysfunction and oxidative stress (Ayala-Peña,
2013; Johri et al., 2013; Tsoi and Chan, 2014).
Early findings that suggested that excitotoxicity might play
an important role in HD were based on the observation that
injection of the KYN metabolite and NMDA receptor agonist
QUIN, as well as L-glu and kainate, into the striatum of rats
generated neuronal degeneration (Coyle and Schwarcz, 1976;
Beal et al., 1986). Beal et al. reported that QUIN, as compared
to NMDA and kainate, induces a rather selective degeneration of
the MSNs rather than general neuronal death (Beal et al., 1986),
thus strongly resembling the pathology of HD. Later, NMDA
receptors were found to be hyperactive and striatal neurons from
different HD mouse models, including those transgenic for a
yeast artificial chromosome (YAC) that leads to over-expression
of full-length htt with extended polyglutamine repeats (Zeron
et al., 2002; Shehadeh et al., 2006), R6/2 mice over-expressing
htt exon 1 with extended polyglutamine repeats as well as in
knock-in mice with increased CAG repeats inserted in the mouse
htt gene (Levine et al., 1999), were shown to be sensitized
to excitotoxicity in vitro. Of note, in vivo, a sensitization to
excitotoxin injection into the striatum was only observed in
the transgenic YAC model of HD (Zeron et al., 2002), whereas
mice over-expressing mutant htt exon 1, R6/1 and R6/2 mice,
(Hansson et al., 1999, 2001b) or N171-82Q mice over-expressing
mutant exon 1 and parts of exon 2 (Jarabek et al., 2004) or the
so-called “shortstop” mouse expressing human N-terminal htt
encoded by exon 1 and 2 with a 128 CAG repeat under the
htt promoter (Slow et al., 2005) actually developed resistance
to striatal excitotoxin injection during aging. However, this
acquired neuroprotection is not specific for NMDA receptor
agonists but extends to other neurotoxic insults (Hansson et al.,
2001a; Petersén et al., 2001) and may represent an adaptive
response to cellular stress.
Rat MSN express high levels of NR2A- and NR2B-containing
NMDA receptors when compared to interneurons in the striatum
(Landwehrmeyer et al., 1995). Correspondingly, NR1 and NR2B
mRNA expression in the neostriatum of HD patients was found
to be prominently decreased which correlated with the loss of
the neurons (Arzberger et al., 1997). Moreover, NMDA receptor-
mediated currents in MSN were demonstrated to be largely
sensitive to the NR2B-specific inhibitor ifenprodil (Zeron et al.,
2002). In HEK293 cells, over-expression of mutant htt increased
NMDA receptor-mediated currents and exacerbated NMDA-
induced cell death only when NR2B- but not when NR2A-
containing NMDA receptors were co-expressed (Chen et al.,
1999; Zeron et al., 2001). One possible explanation for the
increase in NR2B-containing NMDA receptor expression in HD
models is that an extended polyglutamine repeat in htt decreases
its binding to PSD95, a postsynaptic density protein involved
in NMDA and kainate receptor clustering, leading to increased
interaction of PSD95 with the NR2B subunit (Sun et al., 2001;
Fan et al., 2009). More recently, data have been presented that
suggest that not only the subunit composition but also the
localization of NMDA receptors might play an important role in
the deleterious NMDA receptor activity in HD.Milnerwood et al.
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(2010) showed that in acute striatal slice preparations from YAC
transgenic mice with 128 CAG repeats, extrasynaptic NMDA
receptors, especially those containing NR2B, are significantly
increased compared to slices from wild-type mice and YAC mice
expressing htt with 18 CAG repeats. As expected from in vitro
studies (Hardingham et al., 2001), this change was associated
with reduced CREB phosphorylation (Milnerwood et al., 2010).
The increased proportion of NR2B-containing extrasynaptic
NMDA receptors was demonstrated to be associated with an
increased extrasynaptic localization of PSD95 (Fan et al., 2012).
One pathway that might mediate the sensitization to excitotoxic
stimuli downstream of the activation of extrasynaptic NMDA
receptors was identified as activation of p38 MAPK (Fan
et al., 2012). Taken together, multilayered evidence suggests
that mutant htt leads to sensitization of MSN to glutamate
excitotoxicity in part through a relative redistribution of NMDA
receptors, especially those containing an NR2B subunit, from
synaptic to extrasynaptic sites.
The activation of extrasynaptic NMDA receptors in acute
striatal brain slices can be effectively induced in YAC mice with
128 CAG repeats by facilitating spillover of synaptic glutamate by
inhibiting EAATs (Milnerwood et al., 2010). Consequently, it can
be hypothesized that decreased EAAT expression might increase
activation of extrasynaptic NMDA receptors. Interestingly, using
in situ-hybridization, Arzberger et al. found a decrease in
astrocytic EAAT2 mRNA expression in the neostriatum of HD
patients (Arzberger et al., 1997). EAAT2 function was found
to be decreased in striatal synaptosomes of YAC mice over-
expressing human htt with 128 CAG repeats as compared to wild-
type mice, however no changes in EAAT2 protein expression
could be detected. The authors argued that a functionally relevant
decrease in EAAT2 activity in the YAC model of HD was due to
reduced palmitoylation of the transporter (Huang et al., 2010).
In R6/2 mice, others found reduced EAAT2 mRNA and protein
expression (Liévens et al., 2001; Behrens et al., 2002; Shin et al.,
2005; Estrada-Sánchez et al., 2009) associated with decreased
EAAT2 function in synaptosomes (Liévens et al., 2001) or acute
cortico-striatal slices (Shin et al., 2005). However, extracellular
striatal glutamate concentrations were found to be similar to
those of wild-type control mice (Gianfriddo et al., 2004; Shin
et al., 2005) and a reduced glutamate clearance capacity in the
R6/2 mice could only be revealed by treatment with EAAT
inhibitors or glutamate (Behrens et al., 2002; Estrada-Sánchez
et al., 2009). A putative explanation for this finding could be a
decrease in glutamate release via system x−c as recently a decrease
in xCT, the specific subunit of system x−c , was demonstrated
in the striatum of R6/2 mice at the mRNA and protein levels
(Frederick et al., 2014).
As mentioned above, injection of the KYN metabolite QUIN
at supraphysiological concentrations was used as an early animal
model of HD (Beal et al., 1986). This led to further investigations
of KYN metabolism in HD. Interestingly, the QUIN precursor
3HK exacerbates neurodegeneration in the QUIN HD model
(Guidetti and Schwarcz, 1999), while KYNA is protective (Foster
et al., 1984; Schwarcz and Pellicciari, 2002). Guidetti et al.
found that in early-stage HD, as compared to control and
end-stage HD, neostriatal 3HK and QUIN concentrations were
FIGURE 5 | Potential mechanisms that lead to excitotoxicity in HD.
Increased redistribution of NMDA receptors to the extrasynaptic compartment
is thought to be the prevailing mechanism that fosters excitotoxicity in HD.
Although EAAT2 and the glutamate-lowering kynurenine metabolite kynurenic
acid (KYNA) are downregulated, these changes might be compensated for by
a decrease in system x−c expression.
significantly upregulated (Guidetti et al., 2004). Another study
found KYNA levels decreased in autopsied HD striata as well
as in the CSF of HD patients as compared to controls (Beal
et al., 1992). The initial enzyme of the KYN pathway, IDO, is
induced in the striatum of YAC mice with 128 CAG repeats
(Mazarei et al., 2013a). Mice deficient in IDO are less sensitive
to intrastriatal QUIN injection (Mazarei et al., 2013b). Analysis
of KYNmetabolites in different brain regions from three different
mousemodels of HD, R6/2mice, YAC128mice, andHdhQ92 and
HdhQ111 knock-in mice, suggested age-dependent activation of
the KYN pathway. However, the detailed pattern of metabolite
changes differed somewhat among the models with increased
3HK in cortex, striatum, and cerebellum in R6/2 mice whereas
mice expressing full-length mutant htt showed an additional
cortical and striatal upregulation of QUIN (Guidetti et al.,
2006). Moreover, treatment of R6/2 mice with a non-blood
brain barrier permeable KMO inhibitor, JM6, which indirectly
increased cerebral extracellular KYNA concentrations by ∼50%,
was associated with a decrease in extracellular cerebral L-glu,
decreased neurodegeneration and prolonged survival (Zwilling
et al., 2011).
Taken together, the published literature supports the view
that in HD there is a redistribution of NMDA receptors,
especially those containing NR2B, which might activate signaling
pathways that foster neurodegeneration (Figure 5). There is no
consistent evidence that extracellular cerebral L-glu levels are
grossly increased in HD. This might be explained by the fact that
although EAAT2 and KYNA might be downregulated, there is
also a downregulation of system x−c activity. As only very high
levels of QUIN activated NMDA receptors, this KYN metabolite
is unlikely to directly contribute to the excitotoxic load.
PROOF OF CONCEPT EXPERIMENTS
THAT SUPPORT THE HYPOTHESIS OF
CHRONIC GLUTAMATE TOXICITY IN
NEURODEGENERATION
As EAATs have been found to be down-regulated in many
diseases of the nervous system (Sheldon and Robinson, 2007)
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and hypothetically increased L-glu and L-asp clearance should
dampen the excitotoxic component of these diseases, many
researchers have set out to identify compounds that induce
EAAT2, which is the principal EAAT in the brain and most
frequently found to be downregulated (Sheldon and Robinson,
2007; Kim et al., 2011). This has led to the identification of
many compounds that in vitro (Colton et al., 2010; Xing et al.,
2011) or both in vitro and in vivo (Rothstein et al., 2005;
Ganel et al., 2006; Kong et al., 2014) induce astrocytic EAAT2
expression. Some of these have proven to be protective in animal
models of neurodegenerative diseases (Rothstein et al., 2005;
Ganel et al., 2006; Kong et al., 2014). Cef is perhaps the best
studied of these compounds and has been tested in models of
AD (Zumkehr et al., 2015), HD (Miller et al., 2008), and ALS
(Rothstein et al., 2005) with positive results. However, it has
to be kept in mind that none of these compounds has been
extensively screened for its ability to interact with other cellular
pathways that might also be neuroprotective. Of note, Cef has
been shown not only to induce EAAT2 expression but also to
activate the transcription factor Nrf2 (Lewerenz et al., 2009),
which induces the transcription of a plethora of genes involved
in cytoprotection and antioxidant defense (Kensler et al., 2007).
Since oxidative stress is assumed to play a role in many, if
not all, neurodegenerative diseases (Bogdanov et al., 2001; Radi
et al., 2014), this pathway may account for at least some of the
neuroprotection induced by Cef. Indeed, xCT, which is one of the
downstream targets of Nrf2, has been found to be upregulated
by Cef in vitro and in vivo (Lewerenz et al., 2009; Knackstedt
et al., 2010). Another in vitro EAAT2-inducing compound, MS-
153, effectively protected against secondary neurodegeneration
after traumatic brain injury, but through mechanisms other
that EAAT2 upregulation (Fontana et al., 2015). Thus, proof
of concept experiments that unequivocally demonstrate the
pathophysiological role of a chronically increased excitotoxic
input via iGluRs in neurodegenerative diseases require more
specific manipulations of the neurotransmitter physiology.
As described in the Section on “The Concepts of Acute
and Chronic Glutamate Toxicity,” Glud1 Tg mice represent
a model of chronic excitotoxicity mediated by increased
synaptic L-glu release with limited neuronal loss (Bao et al.,
2009). However, this animal model of increased glutamatergic
neurotransmission has not yet been used to test whether Glud1
over-expression exacerbates the phenotype of mouse models
of neurodegenerative diseases. Another genetically engineered
model is the EAAT2-deficient mouse. As described in the Section
on “The Concepts of Acute and Chronic Glutamate Toxicity,”
homozygous EAAT2 knock-out mice suffer from premature
death due to epilepsy and show hippocampal and focal cortical
atrophy (Tanaka et al., 1997; Kiryk et al., 2008; Petr et al., 2015).
Heterozygous EAAT2 knock-outmice however develop normally
and show only mild behavioral abnormalities (Kiryk et al.,
2008). Consequently, this mouse model of mild glutamatergic
hyperfunction has been used in a series of proof of principle
studies that investigated the functional role of glutamate in
animal models of neurodegenerative diseases. ALS mice that
carry both the G93A mSOD1 mutation and a reduced amount
of EAAT2 (SOD1(G93A)/EAAT2±) exhibited an increase in the
rate of motor decline accompanied by earlier motor neuron
loss when compared with single mutant G93A mSOD1 Tg
mice (Pardo et al., 2006). A modest reduction in survival was
also noted in these double mutant mice. When crossed with
transgenic mice expressing mutations of the human amyloid-β
protein precursor and presenilin-1 (AβPPswe/PS11E9), partial
loss of EAAT2 unmasked spatial memory deficits in 6-month-old
mice expressing AβPPswe/PS11E9. These mice also exhibited
an increase in the ratio of detergent-insoluble Aβ42/Aβ40
suggesting that deficits in glutamate transporter function
contribute to early pathogenic processes associated with AD
(Mookherjee et al., 2011). In contrast, the phenotype of the R6/2
HDmousemodel was not altered inmice that contained only one
EAAT2 allele (Petr et al., 2013).
As a complement to these studies, transgenic mice that over-
express EAAT2 specifically in astrocytes via the GFAP promoter
have also been developed (Guo et al., 2003). EAAT2/G93A
mSOD1 double Tg mice showed moderate amelioration of the
ALS-like phenotype with a statistically significant (14 days) delay
in grip strength decline and loss of motor neurons as well
as a reduction in other events including caspase-3 activation
and SOD1 aggregation but not in the onset of paralysis, body
weight decline or an extended life span when compared with
monotransgenic G93A mSOD1 littermates (Guo et al., 2003).
The same EAAT2 transgenic mouse model was used to test
the effect of increased astrocytic L-glu (and L-asp) uptake by
cross-breeding with an animal model of AD, AβPPswe/Indmice.
Increased EAAT2 protein levels significantly improved cognitive
function, restored synaptic integrity, and reduced amyloid
plaques in these AD mice (Takahashi et al., 2015).
In mice in which genetically engineered deletion of xCT
leads to deficiency in the glutamate/cystine antiporter system
x−c , the prominent reduction of extrasynaptic L-glu is associated
with a robust resistance of dopaminergic neurons against 6-
hydroxydopamine-induced neurodegeneration (Massie et al.,
2011), possibly as a result of decreased excitotoxicity. However,
microglial activation has also been shown to be modulated
by system x−c deficiency resulting in a more neuroprotective
phenotype (Mesci et al., 2015) which provides an alternative
explanation for the protective effect of xCT deletion in this
context.
Thus, genetic models support the role of chronic excitotoxicity
in neurodegenerative diseases, especially ALS and AD. Of note,
all of these models represent life-long changes in glutamatergic
neurotransmission. From the therapeutic perspective, these
models cannot predict whether drugs that specifically ameliorate
the glutamatergic tone during the neurodegenerative process
are protective. To this end, either intensive testing of EAAT2-
inducing drugs for their interaction with other signaling
pathways or the development of inducible mouse models with
dampened excitotoxic load are warranted.
SUMMARY
In summary, “glutamatergic” excitatory input on neurons is a
sum of the interaction of several different activators including
the direct activators, L-glu, and L-asp, and the co-activators,
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glycine, and D-serine, on iGluRs and mGluRs. Other pathways
including tryptophan metabolism and, especially, the tryptophan
metabolite KYNA, modulate glutamatergic neurotransmission.
Glutamatergic input on neurons is either via synaptically
released L-glu (and L-asp) acting on synaptic iGluRs or by
non-synaptically released L-glu acting at extrasynaptic L-glu
receptors. The glutamate/cystine antiporter, system x−c , might
be an important determinant of the extrasynaptic cerebral
L-glu concentration. Chronically increased input via iGluRs,
even if it is only moderate, has the propensity to induce
neuronal degeneration, so-called chronic excitotoxicity. In
many neurodegenerative diseases, including HD, AD, and ALS,
multilayered evidence suggests that glutamatergic dysregulation
is an important contributor to disease pathology although the
molecular basis for this varies widely and might be distinct for
each disease and most likely does not represent the only pathway
that leads to neurodegeneration.
However, as specific pharmacological tools or inducible
genetically engineered mouse models that allow manipulation
of glutamatergic input are lacking, it is not known to what
extent L-glu dysregulation contributes to disease progression in
specific mouse models of different neurodegenerative diseases.
Thus, while the idea that chronic excitotoxicity contributes
to multiple neurodegenerative diseases is supported by many
layers of scientific evidence, it is not clear that therapeutic
interventions that re-establish glutamatergic homeostasis during
ongoing neurodegeneration will be effective tools for stopping
the disease process. Besides direct modulators of iGluR activity,
strong candidates for future approaches to treating chronic
excitotoxicity include specific inducers of EAAT2 to stimulate
L-glu and L-asp uptake, inhibitors of system x−c to reduce
L-glu release as well as compounds that aim to decrease
extracellular L-glu by modulating KYN metabolism, e.g., KMO
inhibitors. In addition, it has to be kept in mind that
combinations of these interventions might be required to
obtain clinically significant benefits without evoking adverse side
effects.
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